卡左双多巴控释片联合多巴丝肼片对帕金森病患者血浆Hcy、叶酸水平的影响

doi:10.3969/j.issn.1001-8131.2022.01.005

Abstract
Figure/Table
References
Related Citation (7)

Download: PDF (402 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the effects of Carbidopa and Levodopa Controlled Release Tablets combined with Levodopa and Benserazide Hydrochloride Tablets on plasma homocysteine（Hcy）and folic acid levels in patients with Parkinson's disease（PD）. Methods 86 patients with PD who were diagnosed and treated in the hospital were randomized into combined group and control group,43 cases in each group.The control group was treated with oral Levodopa and Benserazide Hydrochloride Tablets,and the combined group was treated with Carbidopa and Levodopa Controlled Release Tablets combined with Levodopa and Benserazide Hydrochloride Tablets.The total response rates and adverse reactions of the two groups were observed.Meanwhile,cognitive function（MMSE and MoCA scores）and plasma folic acid and Hcy levels of the two groups were compared before and after treatment. Results The total response rate of combined group（88.37%）was significantly higher than that of the control group（69.77%）（P<0.05）.After treatment,folic acid levels of both groups were significantly increased,and Hcy levels were significantly reduced.Besides,the folic acid level of combined group was significantly higher than that of the control group,and Hcy level was significantly lower than the control group（P<0.05）.After treatment,MMSE and MoCA scores of both groups were significantly increased.Besides,the scores of combined group were significantly higher than those of the control group（P<0.05）.There was no significant difference in the total incidence of adverse reactions between the 2 groups（13.95% vs.16.28%）（P>0.05）. Conclusion Carbidopa and Levodopa Controlled Release Tablets combined with Levodopa and Benserazide Hydrochloride Tablets are effective in treatment of PD,which can significantly improve cognitive function and plasma Hcy,folic acid levels.

Key words： Carbidopa and levodopa controlled release tablets Folic acid Parkinson Homocysteine Levodopa and benserazide hydrochloride tablets

Received: 08 December 2020

PACS:

R742.5

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Niu Xiaobo

Cite this article:

Niu Xiaobo. Effects of Carbidopa and Levodopa Controlled Release Tablets Combined With Levodopa and Benserazide Hydrochloride Tablets on Plasma Hcy and Folic Acid Levels in Patients With Parkinson's Disease[J]. journal1, 2022, 42(1): 11-13.

URL:

http://www.hrbyybjb.org.cn/EN/10.3969/j.issn.1001-8131.2022.01.005 OR http://www.hrbyybjb.org.cn/EN/Y2022/V42/I1/11

[1] 王晓,刘卫国,华平,等.帕金森病运动症状进展分析[J].临床神经病学杂志,2016,29(1):52-54.
[2] 王琳晶,陈静,安微,等.头穴电针结合多巴丝肼片治疗帕金森病的临床疗效观察[J].医学综述,2018,24(23):4746-4751.
[3] 蔡辉,杨程,徐婷婷.多巴丝肼片单药与联合卡左双多巴控释片治疗帕金森病的临床效果对比[J].神经损伤与功能重建,2019,14(9):482-483.
[4] 王一沙,刘菲,胡九娇.多巴制剂对帕金森病患者血浆同型半胱氨酸及尿酸的影响[J].实用药物与临床,2018,21(5):533-536.
[5] 中华医学会神经病学分会帕金森病及运动障碍学组,中国医师协会神经内科医师分会帕金森病及运动障碍专业.中国帕金森病的诊断标准(2016版)[J].中华神经科杂志,2016,49(4):268-271.
[6] 佘小云. 卡左双多巴控释片联合多巴丝肼治疗帕金森病的疗效观察[J].现代药物与临床,2018,33(5):1225-1229.
[7] 张彦红,梁伟雄,朱磊,等.蒙特利尔认知评估量表与简易精神状态量表用于筛查血管性认知障碍的比较[J].中国康复医学杂志,2012,27(5):431-436.
[8] 孙洪吉,谢越,张晓红,等.蒙特利尔认知评估量表的条目分析[J].中华老年心脑血管病杂志,2014,16(4):387-390.
[9] 方黎,江选东,李中秋,等.扩散张量成像评估帕金森患者早期病理改变的研究[J].中国医学装备,2018,161(1):66-69.
[10] 李玲,凡子莲,戴东璟,等.多巴丝肼片联合金刚烷胺治疗帕金森病的临床疗效[J].实用心脑肺血管病杂志,2017,25(7):134-135.
[11] 曹亚琨,廖恺.卡左双多巴控释片对帕金森病伴发抑郁患者的效果[J].国际精神病学杂志,2019,46(5):885-886.
[12] 樊润润,胡俊祥,郝永茂,等.卡左双多巴控释片联合多巴丝肼片对帕金森患者认知功能与血清因子水平的影响[J].国际精神病学杂志,2019,46(3):496-498.
[13] 陈坤,许彩梅,王智光.美多巴对帕金森病病人血清叶酸,维生素B₁₂水平的影响分析[J].内蒙古医科大学学报,2017,39(4):366-367.
[14] 杨盛贤,方芳,刘波,等.左旋多巴对老年帕金森病患者认知功能及血浆Hcy、维生素B₁₂、叶酸水平的影响[J].国际精神病学杂志,2017,44(3):474-476.